ストックスクリーナーアプリを入手
232.30
1.73%
3.94
アフターアワーズ：
232.30
前日終値:
$228.36
開ける：
$228.36
24時間の取引高:
105.66K
Relative Volume:
0.49
時価総額：
$4.65B
収益：
$268.09M
当期純損益:
$124.45M
株価収益率:
39.81
EPS:
5.8347
ネットキャッシュフロー:
$38.05M
1週間 パフォーマンス:
-0.01%
1か月 パフォーマンス:
+16.39%
6か月 パフォーマンス:
+22.02%
1年 パフォーマンス:
+118.43%
1日の値動き範囲:
$228.36
$233.06
1週間の範囲:
$220.06
$236.22
52週間の値動き範囲:
$98.89
$247.38
Ligand Pharmaceuticals Inc Stock (LGND) Company Profile
名前
Ligand Pharmaceuticals Inc
セクター
電話
858-550-7500
住所
3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA
Compare LGND vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LGND
Ligand Pharmaceuticals Inc
|
232.30 | 4.58B | 268.09M | 124.45M | 38.05M | 5.8347 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ligand Pharmaceuticals Inc Stock (LGND) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-11 | 開始されました | BofA Securities | Buy |
| 2025-12-09 | 開始されました | Citigroup | Buy |
| 2025-04-10 | 開始されました | Stifel | Buy |
| 2024-10-03 | 開始されました | Oppenheimer | Outperform |
| 2024-07-30 | 開始されました | RBC Capital Mkts | Outperform |
| 2021-04-14 | 再開されました | Stephens | Overweight |
| 2021-02-04 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-10-06 | 開始されました | Barclays | Overweight |
| 2020-03-24 | ダウングレード | Argus | Buy → Hold |
| 2020-03-10 | 開始されました | Guggenheim | Neutral |
| 2020-02-06 | 開始されました | The Benchmark Company | Buy |
| 2019-09-19 | アップグレード | Barclays | Equal Weight → Overweight |
| 2019-06-11 | 開始されました | Barclays | Equal Weight |
| 2019-05-03 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-03-06 | 繰り返されました | H.C. Wainwright | Buy |
| 2018-10-29 | アップグレード | ROTH Capital | Neutral → Buy |
| 2018-10-02 | 繰り返されました | H.C. Wainwright | Buy |
| 2018-09-11 | 繰り返されました | Argus | Buy |
| 2018-08-17 | 開始されました | Goldman | Neutral |
| 2018-08-08 | ダウングレード | ROTH Capital | Buy → Neutral |
| 2018-06-21 | 開始されました | Argus | Buy |
| 2017-12-27 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-09-05 | 再開されました | H.C. Wainwright | Buy |
| 2016-10-05 | 繰り返されました | H.C. Wainwright | Buy |
| 2016-08-05 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2016-03-11 | 開始されました | Sidoti | Buy |
| 2016-03-03 | 開始されました | H.C. Wainwright | Buy |
すべてを表示
Ligand Pharmaceuticals Inc (LGND) 最新ニュース
Ligand CEO joins Palvella chief at May 6 investor fireside chat - Stock Titan
Ligand to Participate in May Investor Conferences - Yahoo Finance
Ligand to buy XOMA Royalty for $39/share - MSN
CLO Andrew Reardon nets 5,000-share sale at Ligand (NASDAQ: LGND) - Stock Titan
Ligand Pharmaceuticals CLO Andrew Reardon sells $1.16m in stock - Investing.com
Villere St Denis Liquidates $18 Million Euronet Worldwide Stake, According to Recent SEC Filing - The Motley Fool
MSN Money - MSN
LGND PE Ratio & Valuation, Is LGND Overvalued - Intellectia AI
Ligand Pharmaceuticals Incorporated $LGND Shares Sold by Kornitzer Capital Management Inc. KS - MarketBeat
XOMA (XOMA) holders offered $39 cash plus CVRs in Ligand buyout - Stock Titan
Ligand Pharmaceuticals Launches Takeover Plan at XOMA Royalty Corporation with 47.0% Stake - TradingView
Ligand Pharma Ends TR‑Beta License With Viking Therapeutics - The Globe and Mail
LGND (NASDAQ) Rule 144 notice lists 467 common shares and dated sales - Stock Titan
Vanguard reports 5.56% stake in Ligand Pharmaceuticals (NASDAQ: LGND) - Stock Titan
Vanguard Capital Management files Schedule 13G on Ligand (LGND) showing 5% stake - Stock Titan
HC Wainwright Brokers Increase Earnings Estimates for LGND - MarketBeat
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Ligand bets on royalty growth with XOMA buyout worth over $700 million - MSN
[8-K] LIGAND PHARMACEUTICALS INC Reports Material Event - Stock Titan
LGND Maintained by HC Wainwright & Co. -- Price Target Raised to $289 - GuruFocus
HC Wainwright Issues Positive Forecast for Ligand Pharmaceuticals (NASDAQ:LGND) Stock Price - MarketBeat
Ligand Pharmaceuticals is buying Xoma for nearly $740 million - MSN
Ligand Pharmaceuticals (NASDAQ:LGND) Shares Gap DownHere's Why - MarketBeat
LGND: XOMA Buy Adds 100+ Assets - Smartkarma
Moody Aldrich Partners LLC Has $3.70 Million Stock Holdings in Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Ligand Pharmaceuticals to buy XOMA Royalty in $740M all-cash deal: WSJ - MSN
LGND Maintained by RBC Capital -- Price Target Raised to $252 - GuruFocus
Ligand to acquire XOMA Royalty - The Pharma Letter
Royal Bank Of Canada Issues Positive Forecast for Ligand Pharmaceuticals (NASDAQ:LGND) Stock Price - MarketBeat
Ligand Pharmaceuticals And 2 Other Stocks That May Be Trading At An Estimated Discount - Yahoo Finance
RBC Raises Price Target on Ligand Pharmaceuticals to $252 From $235, Keeps Outperform Rating - Moomoo
RBC Capital raises Ligand Pharma stock price target on XOMA deal - Investing.com Canada
Ligand Pharmaceuticals to Buy XOMA Royalty for $39/Share, Lifts 2026 Guidance and EPS Outlook - Yahoo Finance
Why Ligand's $739M Xoma buy matters for growth - Axios
BofA raises Ligand Pharma stock price target on XOMA acquisition - Investing.com
Stifel raises Ligand Pharma stock price target on XOMA acquisition - Investing.com UK
BofA raises Ligand Pharma stock price target on XOMA acquisition By Investing.com - Investing.com Canada
Stifel raises Ligand Pharma stock price target on XOMA acquisition By Investing.com - Investing.com India
Ligand Pharmaceuticals (NASDAQ:LGND) Updates FY 2026 Earnings Guidance - MarketBeat
Ligand Pharma to acquire fellow biotech royalty rights buyer XOMA for $739 million - 104.1 WIKY
Ligand Bets On Royalty Growth With XOMA Buyout Worth Over $700 Million - Benzinga
Ligand Pharmaceuticals Incorporated entered into a definitive agreement to acquire XOMA Royalty Corporation for approximately $470 million from BVF Partners L.P. and others. - marketscreener.com
Ligand Pharmaceuticals Acquires Zoma for $740 Million - GuruFocus
Ligand Pharmaceuticals (LGND) to Acquire Xoma Royalty for $39 pe - GuruFocus
Ligand Pharmaceuticals stock hits 52-week high at 240.25 USD By Investing.com - Investing.com Canada
Ligand Pharmaceuticals to Acquire XOMA Royalty for $39 Per Share Plus CVRs - TradingView
Ligand strikes $739M deal for Xoma Royalty - Axios
Ligand Pharmaceuticals to Acquire Xoma Royalty for 739 Million Dollars - HarianBasis.co
Ligand (Nasdaq: LGND) to acquire XOMA Royalty in $739M, EPS‑accretive deal - Stock Titan
Ligand Pharmaceuticals (LGND) to Acquire XOMA Royalty for $39 pe - GuruFocus
Ligand Pharmaceuticals buying Xoma Royalty for $739 million - Yahoo Finance
Ligand Pharmaceuticals Inc (LGND) 財務データ
収益
当期純利益
現金流量
EPS
0.14%
0.48%
大文字化:
|
ボリューム (24 時間):